The objectives of this paper is to investigate, demonstrate, and compare the mechanism of action of phytocannabinoids as antidiabetic and anti-obesity agents in preadipocytes and adipocytes, relative to rosiglitazone and metformin. Briefly, cannabis extract, Δ 9 -tetrahydrocannabinol and cannabidiol (in very low dosages) were shown to promote glucose uptake higher or to equivalent levels, reduce fat accumulation, and reverse the insulin-resistant state of 3T3-L1 cells more effectively, relative to rosiglitazone and metformin. The phytocannabinoids had a more pronounced effect in preadipocytes undifferentiated model rather than the differentiated model. They induced a protective effect at the mitochondrial level by preventing overactivity of the succinate dehydrogenase pathway (p < .01), unlike rosiglitazone, through activation of the glycerol-3-phosphate dehydrogenase shuttling system. An increase in oxygen consumption and an increased expression of beta to alpha adrenoceptors (p < .05) in treated cells were noted. These findings contribute toward understanding the mechanism of action of phytocannabinoids in fat cells and highlight the antidiabetic and anti-obesity properties of various phytocannabinoids that could potentially support the treatment of obesity-related insulin resistance.
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The increasing prevalence of diabetes and obesity-related insulinresistance accounts for millions of deaths worldwide and emphasize the need to develop an efficient and safe antidiabetic drug.
Currently, there are no antidiabetic drugs on the market that are free of side effects. Rosiglitazone (Rosi) forms part of the thiazolidinedione (TZDs) family, and its use has been linked with increased weight gain (Moller, 2001) , an unwanted side effect in obesity-linked insulin-resistance, as well as an increased rate of heart failure and strokes in diabetic patients (Graham et al., 2010) . Metformin (MET) has been associated with the occurrence of lactic acidosis in diabetic patients (Moller, 2001) . Recent studies have focused on the changes in adipose tissue to provide new therapeutic alternatives.
There are 3 types of fat cells, which have been identified, namely, brown, beige, and white fat cells (Wu et al., 2012) . The functions of brown fat cells are commonly considered to be specialized for thermogenesis, whereas white fat cells primarily play a role in energy storage and as an important endocrine organ (Qian, Huang, & Tang, 2015; Spiegelman, 2013) . Beige fat cells, depending on the stimuli present, can perform thermogenesis as well as store energy as fat (Sidossis & Kajimura, 2015) . The phenotypic switch of white preadipocytes to beige adipocytes has recently been considered as an attractive therapeutic target to combat the prevailing worldwide problem of obesity and insulin resistance. When considering the development of a treatment for obesity and obesity-related insulin resistance (ideally at the adipose tissue level), the drug should be able to regulate blood glucose levels (Chadwick, Roux, van de Venter, Louw, & Oelofsen, 2007) without promoting excessive fat deposition (Moller, 2001 ).
Cannabis sativa is a plant that contains a complex mixture of more than 100 phytocannabinoids (Hill, Williams, Whalley, & Stephens, 2012) with the main active constituents being cannabidiol (CBD), cannabinol (CBN), and Δ 9 -tetrahydrocannabinol (THC). THC is the main psychoactive compound whereas CBN is weakly psychoactive (Hollister, 1973) , and CBD is nonintoxicating (Russo, 2017) . Studies have shown that CBD plays an important role in preventing or reducing the psychoactivity associated with the presence of THC (Russo, 2011) . Previous studies have shown that a cannabis extract (CE) has beneficial effects in improving insulin sensitivity of tissues (Gallant, 2010) , inducing weight loss in diet-induced obese rats and protecting beta pancreatic cells from the deleterious effects of hyperglycemia in vivo (Levendal, Schumann, Donath, & Frost, 2012) .
In this study, we investigate the time-dependent effects of various phytocannabinoids, an endocannabinoid and a terpenoid, Marrubiin (MA), on the modulation of carbohydrate and fat metabolism, relative to Rosi and MET, in preadipocyte and differentiated 3T3-L1 cells.
| MATERIALS AND METHODS

| General note
The 3T3-L1 cells (a kind donation from Professor Nigel Crowther)
were routinely maintained and subcultured as previously described (Celis et al., 2005; Tamori, Masugi, Nishino, & Kasuga, 2002) .
| Cannabis extraction and quantification
The cannabis extraction was performed using chloroform as the organic solvent and quantified using reverse-phase high-performance liquid chromatography (Gallant, Odei-Addo, Frost, & Levendal, 2009; Levendal et al., 2012 ) on a μBondapak C18 (10 μm × 4.6 mm × 250 mm)
column. Acetonitrile and 0.01-M phosphate buffer in the ratio of 70:30 at a flowrate of 1 ml/min was used as the elution buffer. The absorbance was monitored at A 214nm . Commercial cannabinoids, namely, THC, CBD, and CBN, were used to set up calibration curves.
| Experimental conditions
The selected treatments included Rosi (1 μM), CE (1.32 μg/ml), THC (20 ng/ml); CBN (20 ng/ml), CBD (20 ng/ml), 2AG (3 μM), MA
(1 μM), and MET (1 μM). Pure commercial cannabinoids as well as the CE were used as treatments for comparative purposes to ascertain which of the major cannabinoids were effecting the change in fat metabolism. The concentration of the pure cannabinoids chosen was equivalent to that present in the CE. In addition, previous studies were conducted to ascertain the most effective concentrations in adipocytes (Gallant et al., 2009 ). The CE contains THC:
CBN: CBD in the ratio 1:10:1, and the concentration of CE were exposed to cells containing 20-ng/ml THC, 200-ng/ml CBN, and 20-ng/ml CBD. Dimethyl sulfoxide is used as the vehicle control in all experiments.
| Study design
Preadipocytes cell model: 3T3-L1 cells were seeded in 48-well plates and allowed to reach postconfluence. The cells were then exposed to the different conditions for 7 and 14 days. Media was changed every 3 days.
Differentiated cell model (mimicking obese state): 3T3-L1 cells were seeded in 48-well plates and once postconfluent, the cells were exposed to a modified differentiation cocktail containing Dulbecco's Modified Eagle Medium (DMEM), 10% fetal bovine serum and Rosi (1μM) for 7 days, with media change every 3 days. Once differentiated, the cells were then exposed to the different experimental conditions for 7 days, with media changed every 3 days.
Insulin-resistant cell model: 3T3-L1 preadipocytes were differentiated using a modified protocol of differentiation cocktail, containing DMEM, dexamethasone (0.25 μmol/L), insulin (10 μg/mL), isobutylmethylxanthine (0.5 mmol/L), and 10% fetal bovine serum.
After 3 days of induction, cells were maintained in media supplemented with insulin (60 μU/ml) for 3 days (Gallant, 2010; Wu et al., 2012) . Differentiated 3T3-L1 adipocytes were then exposed to 20-ng/ml tumor necrosis factor alpha (TNFα; Biocom Biotech) for 24 hr (Gallant, 2010) to induce insulin resistance. Thereafter, insulin-resistant cells were exposed to the different experimental conditions for 24 hr. Reduced glucose uptake of the TNFα-treated cells, relative to untreated cells, was deemed as an indicator of reduced insulin sensitivity of the adipocytes. The reason for using isobutylmethylxanthine, dexamethasone, and insulin as differentiation cocktail instead of DMEM supplemented with Rosi as in the "differentiated cell model," is due to the fact that Rosi, being an antidiabetic agent, was exerting a protective effect on the 3T3-L1 cells and was preventing the cells from becoming insulin-resistant when exposed to TNFα.
| MTT assay
Briefly, at the end of each experiment, the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed (Gallant, 2010 ).
| Glucose uptake assay
The glucose uptake assay was performed, and the data were normalized to cell number (data not shown) as well as to protein content.
Briefly, the cells were exposed to glucose-free media for 1 hr and then exposed to media containing 8-mM glucose and 60 μU/ml insulin for 1 hr. After the incubation period, the remaining glucose in the media was quantified using the Glu-cinet reagent (Gallant, 2010) .
| Oil Red O quantification
After treatments, Oil Red O quantification was performed. Briefly, cells were washed with phosphate buffer saline and fixed in 4% formaldehyde overnight. Oil Red O-working solution was prepared as previously described (Zebisch, Voigt, Wabitsch, & Brandsch, 2012) .
Data were normalized to cell number (data not shown) as well as to protein content.
| Protein extraction
Experimental conditions were similar to that mentioned in Section 2.3, with cells seeded into 10-cm petri dishes, with media changed every 3 days. After the exposure period, cells were lysed as previously described (Wise & Green, 1979) . The pellet and supernatant were used to assay succinate dehydrogenase (SDH) and glycerol-3-phosphate (G3PDH) activity, respectively. The total protein concentration was determined using the bicinchoninic acid assay (Olson & Markwell, 2007) , and the specific activity was calculated.
| Succinate dehydrogenase assay
The enzymatic assay was completed according to a modified protocol previously described (Green & Narahara, 1980) . Briefly, pellets were resuspended in 0.05-M phosphate buffer (pH 7.5), 0.01-M sodium succinate in phosphate buffer, 2.5-mg/L p-iodonitrotetrazolium (INT) violet (Sigma); and the protein were incubated separately at 37°C
for 5 min after which they were mixed, and the change in absorbance was monitored at A 490nm with data collected every 4 s for 10 min using a PowerWave xs microtiter plate reader (Biotek). In order to calculate the specific activity of SDH, the change in absorbance per minute derived from the progress curves was divided by the total protein content of the test sample and multiplied by the extinction coefficient of INT formazan (Bergmeyer, 2012) .
| G3PDH assay
The assay was completed as previously described (Wise & Green, 1979) . Briefly, 0.12-mM nicotinamide adenine dinucleotide, 0.2-mM dihydroxyacetone phosphate (Sigma), and supernatant were incubated separately at 37°C for 5 min after which they were combined and the change in absorbance was measured at A 340nm for 10 min with data collected every 4 s using a PowerWave xs microtiter plate reader. To calculate the specific activity of G3PDH, the change in absorbance per minute derived from the progress curves was divided by the total protein content of the test sample and multiplied by the extinction coefficient of nicotinamide adenine dinucleotide. were exposed to 20-ng/ml TNFα for 24 hr to induce insulin resistance, and it was confirmed with a reduction in insulin-induced glucose uptake. The insulinresistant model of 3T3-L1 cells was then exposed to the different treatments for 24 hr, and glucose uptake assay was performed. Values are mean ± standard deviation (n = 3). *p < .05, **p < .01, ***p < .001 relative to untreated, # p < . 
| Ratio of beta to alpha adrenoceptors assay
Adrenergic beta-2-receptor Eliza kit (antibodies online) and adrenergic alpha-2-A receptor Eliza kit (antibodies online) were used to determine the ratio of beta to alpha adrenoceptors expressed in control and treated
cells. The total protein concentration of all the samples was quantified using the bicinchoninic acid assay (Olson & Markwell, 2007) . The concentrations of the beta and alpha adrenoceptors expressed by the cells were extrapolated from the respective standard curves, and the data were normalized using the total protein concentration of the test samples.
| Statistical analyses
A minimum of 3 experiments were completed for each of the parameters investigated, having 6 repeats per condition. The results are expressed as the mean ± standard deviation. One-way analysis of variance with post hoc analysis (Tukey test) was performed to determine the p values for the appropriate experiments.
| RESULTS AND DISCUSSIONS
To investigate the time dependent effect of phytocannabinoids, different 3T3-L1 cell model were exposed to the different treatments for 7
and/or 14 days. Before experimentation commenced, the CE was quantified for selected phytocannabinoids (Figure 1 ). (Figure 2e,f) . Potentially, a longer treatment period was required to observe a significant change in the differentiated model. It can therefore be noted that these cannabinoids promote lipolysis to a greater extent than Rosi, despite improving glucose uptake. This may be beneficial in cases of obesity-induced insulin-resistant individuals.
In the insulin-resistant cell model (Figure 2k ), all the treatments, except MET, were able to reverse the insulin-resistant state of the cells more effectively than Rosi by significantly promoting higher glucose FIGURE 3 Treatments modulate mitochondrial activity in 3T3-L1 cells possibly reducing oxidative stress. 3T3-L1 postconfluent preadipocytes were exposed for (a,d) 7 days and for (b,e) 14 days to the different compounds [Rosi: rosiglitazone (1 μM), CE: cannabis extract (1.32 μg/ml), THC: Δ
9
-tetrahydrocannabinol (20 ng/ml), CBN: cannabinol (20 ng/ml), CBD: cannabidiol (20 ng/ml), 2AG: 2-arachidonoyl-glycerol (3 μM), MA: marrubiin (1 μM), and MET: metformin (1 μM)]. Differentiated 3T3-L1 adipocytes (using rosiglitazone as the inducer of differentiation) were exposed for 7 days to the different compounds (c,f). Protein lysates were isolated, and the activity of succinate dehydrogenase (SDH; a-c) and glycerol-3-phosphate dehydrogenase (G3PDH; d-f) was monitored as described in Section 2.9 and 2.10. Values are mean ± standard deviation (n = 3). *p < .05, **p < .01, ***p < .001 relative to untreated and # p < .05, ## p < .01, ### p < .001 relative to Rosi uptake, relative to the negative control (TNFα). This was not observed for MET thus suggesting that MET has a different mechanism of action compared with TZDs, because MET is a biguanide (Campbell, White, & Saulie, 1996) , and it mainly targets the liver instead of fat where the insulin sensitivity of the liver is improved (Tiikkainen et al., 2004) .
Studies have shown that metformin treatment was unable to induce adiponectin expression in fat tissue (Tiikkainen et al., 2004) , which may explain its inefficacy in improving glucose uptake in insulin-resistant 3T3-L1 cell. From the live micrographs of the 3T3-L1 cells (Figure 2g ,h,j) and 3T3-L1 cells stained with Oil Red O (Figure 2i ), marked morphological differences were observed in cells treated with phytocannabinoids showing smaller and more multilocular fat droplet formation, relative to Rosi-treated cells. These results (Figure 2) confirm the increase in weight gain among diabetic patients using Rosi as a treatment.
To better understand the mechanism of action through which phytocannabinoids can promote glucose utilization rather than storage in 3T3-L1 cells, the activity SDH G3PDH, involved in oxidative phosphorylation was investigated. From Figure 3 , it is interesting to note how Rosi promotes overactivity of the SDH activity while impairing the G3PDH shuttling system, in a time-dependent manner. Previous studies have shown that TZDs can improve mitochondrial function, with Rosi upregulating genes responsible for mitochondrial biogenesis, resulting in significantly increased SDH activity and increased oxidation in muscle fat (Mensink et al., 2007) . However, increased mitochondrial oxidative capacity has been associated with increased oxidative stress, due to increased reactive oxygen spe- respiratory chain, which leads to increasing oxidative stress due to elevated ROS production (Satapati et al., 2012) . The increased SDH activity could potentially explain why the use of Rosi has been associated with heart failures in diabetic patients. The phytocannabinoids, endocannabinoid, terpenoid as well as MET treatments were effective in modulating the SDH activity to a certain degree thereby providing a possible mechanism via which excessive ROS can be prevented.
The G3PDH shuttling system plays an important role in modulating the balance between fatty acid oxidation and lipid synthesis to protect the cells against high intracellular free fatty acids (Houstek, Cannon, & Lindberg, 1975) . G3PDH is highly expressed in the brown adipose tissue of mammals with possible thermogenic characteristics (Mráček, Drahota, & Houštěk, 2013) . This was also noted in mice with overexpressed G3PDH activity having a leaner and enhanced thermogenic ability (Lowell & Spiegelman, 2000) . Activation of the G3PDH
shuttling system may be a mechanism to prevent overactivity of the TCA cycle and SDH. We also noted the ability of THC, 2AG, and MA to promote the G3PDH shuttling system over time (Figure 3e ), thus
showing the time-dependent modulatory effect of these compounds on cellular mitochondrial energetics. In the case of the 7-day differentiated 3T3-L1 cell model (Figure 3f ), the G3PDH activity remained significantly lower (approximately 10-fold) than untreated cells. All experimental treatments resulted in G3PDH levels that were similar to that of Rosi. Because the 3T3-L1 cells were differentiated using rosiglitazone as the inducer of differentiation, it can be postulated that Rosi impaired the G3PDH shuttling system during adipogenesis, as seen in Figure 3e , and the phytocannabinoids treatments were then ineffective in reversing or enhancing the activity of G3PDH. It would be of interest to investigate whether a different differentiation cocktail other than Rosi would influence G3PDH activity.
From the oxygen consumption study (Figure 4a) Oxygen consumption and the ratio of Beta to alpha adrenoceptors expressed in 3T3-L1 treated cells. 3T3-L1 postconfluent preadipocytes were exposed to the different compounds [Rosi: rosiglitazone (1 μM), CE: cannabis extract (1.32 μg/ ml), THC: Δ
-tetrahydrocannabinol (20 ng/ml), CBN: cannabinol (20 ng/ml), CBD: cannabidiol (20 ng/ml), 2AG: 2-arachidonoyl-glycerol (3 μM), MA: marrubiin (1 μM), and MET: metformin (1 μM)] for 14 days. (a) Rate of oxygen consumption and (b) the ratio of beta to alpha adrenoceptors expressed were investigated as described in the Section 2.11 and 2.12. Values are mean ± standard deviation (n = 3). *p < .05, **p < .01, ***p < .001 relative to untreated and # p < .05, ## p < .01, ### p < .001 relative to Rosi was shown to increase oxygen consumption in white adipose tissue, and the increase was associated with mitochondrial remodeling and biogenesis (Wilson-Fritch et al., 2004) . However, an increase in TCA cycle flux resulting in increased oxygen consumption may suggest impaired mitochondrial oxidative capacity (Satapati et al., 2012) . As
Rosi increased SDH activity, impairing the G3PDH shuttling system ( Figure 3 ) and showed increased oxygen consumption, it can be postulated that the activation of SDH is the main pathway through which adenosine triphosphate is generated and is used for processes such as lipogenesis, accounting for the increase in fat accumulation (Figure 2 ). In contrast, phytocannabinoids treatments, in a time-dependent manner, (for example CBD: preadipocytes 7 days and THC: preadipocytes 14 days) modulate SDH activity, increase the G3PDH pathway activation and increase oxygen consumption, signaling an increased uncoupling effect in the mitochondria and may therefore explain the reduced fat accumulation in cells despite promoting higher glucose uptake or fairly similar compared with Rosi.
The adrenergic system is a highly regulated system, which plays an important role in energy metabolism and maintaining homeostasis within the adipose tissue. Activation of beta and alpha adrenoceptors promote lipolysis and lipogenesis, respectively (Langin, 2006) .
Previous studies have shown that overexpression of alpha adrenoceptors was linked to the development of Type 2 diabetes (Rosengren et al., 2010) . We investigated the effect of the different treatments on the ratio of beta and alpha adrenoceptors expression in the 14-day 3T3-L1 preadipocytes model (Figure 4b ), which might account for the difference in fat accumulation, SDH, and G3PDH activity as well as differences in the level of oxygen consumption.
CE, THC, and CBD treatments caused a significant increase in the ratio of beta to alpha adrenoceptors expression when compared with Rosi-treated cells.
| CONCLUSION
Based on all the findings within this study, we therefore propose that the phytocannabinoids exert their antidiabetic/obesity effect (in a time-dependent manner) through the activation of the beta-adrenergic signaling pathway resulting in an increase in the ratio of beta to alpha adrenoceptors as well as the activation of the G3PDH shuttling system, accounting for the lower level of fat accumulation relative to Rosi. Additional research is required to understand the mechanism of action of phytocannabinoids inducing these changes in adipocyte metabolism. Further investigations should consider the level of expression of markers of beige adipocytes in order to investigate whether phytocannabinoids treatment promote fat beigeing. The ability of phytocannabinoids to potentially induce a phenotype switch and to act as insulin-sensitizing agent might be useful in the treatment of obesity-related insulin resistance.
